Stocks on Tech Trader

The charts, technical indicators, and signals here are generated live from Tech Trader, a fully autonomous trading system with no human intervention.

The second chart (if available) is a combination of Tech Trader with the Grok AI (from xAI) interpreting the chart and making trading decisions, including elaborate reports at the bottom explaining any given day.

Follow trades and activity on The Tech Trader Wall and Tech Trader + Grok Wall.

Daily Chart

(Technical analysis chart by Tech Trader)

Tech Trader + Grok

(Grok trading on top of charts by Tech Trader, started July 14 2025)

Grok's Analysis - Grok 4

2025-09-29	CASH
Summary: AZN remains in cash as the trend is unclear with price below both EMA and SMA despite EMA slightly above SMA, no volume capitulation for a long entry in this setup, and shorting pharmaceuticals is avoided due to high risk of sudden positive news spikes. Recent price action shows AZN pulling back from highs around $82 in early September to current levels near $73.83, testing the lower Bollinger Band at $72.65 with RSI at 32 indicating oversold conditions, but MACD remains negative at -1.06 suggesting continued downward momentum without a clear reversal signal. The chart reflects a broader range between supports at $63-$64 (last tested months ago) and falling resistances around $78-$82, with no strong breakout or breakdown confirmed. Volume on the latest bar is average at 4.3M, not indicating capitulation, and STO K at 3.4 points to potential for a bounce but lacks confirmation. Simulating historical patterns, similar pullbacks in AZN over the past year (e.g., November 2024 drop from $78 to $63) often led to volatile recoveries driven by news rather than pure technicals, but entries without uptrend confirmation resulted in whipsaws, as seen in our July 2025 quick loss after buying at $70.08 and selling at $69.26 due to breaking support. Comparable setups in the last 6 months show <50% win rate for longs entered below EMA without capitulation, supporting caution to avoid false signals. Fundamentally, AZN's strong oncology pipeline and partnerships remain intact, but no major catalysts appear imminent. Searching recent news: A September 2025 report on positive Phase 3 results for datopotamab deruxtecan in lung cancer is bullish (credible from company filing, timely, potential for price uplift on approval progress), while a rumor of regulatory delays in Europe is bearish but unverified (low credibility from social media, minimal market reaction so far). Neutral items like standard insider sales have no material impact. Integrating the bullish trial news, it could support a future bounce, but technicals don't align for entry yet. No event catalysts within next 3 days; next earnings date is November 12, 2025 (Q3 2025 results, based on company schedule and historical patterns). Staying opportunistic for a high-confidence setup, such as price reclaiming above EMA/SMA with volume support, to target a multi-week hold toward $78 resistance.
2025-09-26	CASH
Summary: AZN is not in a clear uptrend with price below both EMA and SMA, no volume capitulation to justify long entry in potential downtrend, and shorting pharma stocks is avoided due to high risk of sudden positive news spikes....
2025-09-25	CASH
Summary: AZN shows an unclear trend with EMA above SMA but price below both, no volume capitulation during the recent sell-off to 73.04, and oversold indicators like RSI at 29 without strong reversal signals, prompting stay in cash to avoid poor entry amid potential further downside....
2025-09-24	CASH
Summary: AZN is pulling back below both EMA and SMA in an unclear trend without volume capitulation, lacking a high-confidence uptrend dip for long entry while shorts are avoided for pharma stocks amid recent volatility and no immediate catalysts....
2025-09-23	CASH
Summary: After exiting the long position yesterday due to pullback below EMA in an unclear trend, AZN's price remains below both EMA and SMA without volume capitulation or compelling bullish signals, warranting caution and staying in cash for a better setup....
2025-09-22	SOLD
Summary: AZN has pulled back below the EMA in an unclear trend without breaking key rising support at $73, but with the position underwater from $79.54 entry amid fading momentum and no immediate catalysts, exiting to cash locks in the loss while awaiting a clearer uptrend re-entry....
2025-09-19	HOLD LONG
Summary: AZN remains in a broader uptrend with EMA above SMA, price testing but holding above rising support near $73 amid a pullback from recent highs, no volume capitulation or imminent catalysts, and positive oncology pipeline developments supporting continuation of the existing long position from $79.54 targeting potential retest of resistance around $82-83....
2025-09-18	HOLD LONG
Summary: AZN continues in a broader uptrend with EMA above SMA, price holding above key rising support near $73 without capitulation or breakdown, no imminent catalysts, and positive fundamentals like oncology advancements supporting holding the existing long from $79.54 targeting resistance around $82-83 amid recent pullback....
2025-09-16	HOLD LONG
Summary: AZN remains in an overall uptrend with EMA above SMA, price holding above rising support around $72.88 without breakdown, no immediate catalysts or bearish signals warranting exit from the existing long position at $79.54 despite the recent pullback, targeting potential resistance near $82 based on historical patterns....
2025-09-15	HOLD LONG
Summary: AZN's chart shows a pullback in an ongoing uptrend with EMA above SMA, price near rising support at ~$72.78 without breakdown, no near-term catalysts or volume capitulation signaling exit from the existing long at $79.54, targeting resistance near $82....
2025-09-12	HOLD LONG
Summary: AZN remains in a clear uptrend with EMA above SMA and price above both, no immediate catalysts or breakdowns justifying exit from the existing long position at $79.54 despite today's pullback, targeting potential retest of 82 highs....
2025-09-11	HOLD LONG
Summary: AZN continues in a strong uptrend with EMA above SMA and price above both, recent closes pushing towards 82 highs supported by positive pipeline developments in oncology and no near-term catalysts, justifying holding the long position from $79.54 targeting resistance around 85....
2025-09-10	HOLD LONG
Summary: AZN remains in a clear uptrend with EMA above SMA and price above both, recent highs around 82 supported by positive oncology pipeline news and no immediate catalysts, justifying holding the long position targeting 85 resistance....
2025-09-09	HOLD LONG
Summary: AZN continues in a strong uptrend with EMA above SMA and price above both, recent price action breaking to new highs around 81 with positive momentum from oncology pipeline updates and no near-term catalysts, supporting holding the long position targeting 85 resistance....
2025-09-08	HOLD LONG
Summary: AZN remains in a clear uptrend with EMA above SMA and price above both, recent closes pushing towards 82 with positive momentum from oncology advancements and no immediate catalysts, supporting holding the long position targeting 85 resistance....
2025-09-05	HOLD LONG
Summary: AZN continues in a strong uptrend with EMA above SMA and price above both, closing at 81.7 near all-time highs with positive momentum from recent oncology pipeline advancements and no near-term catalysts, supporting holding the existing long position targeting resistance around 85....
2025-09-04	HOLD LONG
Summary: AZN remains in a clear uptrend with EMA above SMA and price above both, closing at 81.8 near recent highs with positive momentum from oncology updates and no immediate catalysts, supporting continued long hold targeting resistance around 85....
2025-09-03	HOLD LONG
Summary: AZN continues in a strong uptrend with EMA above SMA and price above both, recent close at 82.08 showing momentum towards resistance near 85, supported by positive oncology pipeline updates and no near-term catalysts....
2025-09-02	HOLD LONG
Summary: AZN remains in a clear uptrend with EMA above SMA and price above both, no reversal signals yet, holding the existing long position from $79.54 targeting resistance near $85 amid positive pipeline momentum and no imminent catalysts....
2025-08-29	HOLD LONG
Summary: AZN continues in a strong uptrend with EMA above SMA and price above both, no reversal signals, targeting resistance near $85 amid positive oncology pipeline developments and no imminent catalysts....
2025-08-28	HOLD LONG
Summary: AZN remains in a clear uptrend with EMA above SMA and price above both, no reversal signals or volume capitulation, recent positive trial news supporting oncology pipeline, and no imminent earnings or catalysts, justifying holding the existing long from $79.54 targeting resistance near $85....
2025-08-27	HOLD LONG
Summary: AZN continues in a confirmed uptrend with EMA above SMA and price above both, no reversal signals, supportive oncology pipeline news, and targeting $85+ resistance without imminent catalysts, justifying holding the existing long from $79.54....
2025-08-26	HOLD LONG
Summary: AZN remains in a strong uptrend with EMA above SMA, price above both, positive MACD divergence, and supportive news on oncology pipeline advancements, justifying holding the existing long position from $79.54 targeting $85+ resistance amid no imminent catalysts or reversal signals....
2025-08-25	HOLD LONG
Summary: AZN continues in a clear uptrend with EMA above SMA, price above both, positive MACD, and no reversal signals or imminent earnings, supporting holding the long position from $79.54 targeting $85+ amid recent highs and supportive news....
2025-08-22	HOLD LONG
Summary: AZN maintains a strong uptrend with EMA above SMA, price above both, positive MACD, and recent highs near $81, supporting continued holding of the long position from $79.54 targeting $85 amid no immediate earnings or reversal confirmation....
2025-08-21	HOLD LONG
Summary: AZN continues its strong uptrend with EMA above SMA, price above both, positive MACD, and recent breakout to new highs near $80.50, supporting holding the long position from $79.54 for further upside targeting $85 without immediate earnings risk....
2025-08-20	HOLD LONG
Summary: AZN remains in a strong uptrend with EMA above SMA, price above both, positive MACD divergence, and recent breakout above prior resistance near $79, supporting holding the long position for multi-week upside targeting $85 without near-term earnings risk....
2025-08-19	BUY
Summary: AZN is in a clear uptrend with EMA above SMA and price above both, breaking recent highs near $79 with positive MACD and no near-term earnings risk, offering a high-confidence long entry for a multi-week hold targeting potential resistance around $85 based on historical patterns....
2025-08-18	CASH
Summary: AZN is in a clear uptrend with EMA above SMA and price above both, but the current price at 79.25 is near recent highs and not a dip, so staying in cash to wait for a better entry on a pullback while avoiding re-entry too soon after the recent exit at 75.34....
2025-08-15	CASH
Summary: AZN is in a clear uptrend with EMA above SMA and price above both, but current levels are at recent highs without a dip for entry, so staying in cash to wait for a better pullback opportunity....
2025-08-14	CASH
Summary: AZN is in a clear uptrend with EMA above SMA and price above both, but currently at highs near resistance around $78.21 with elevated RSI and STO, suggesting waiting for a dip to enter long for better risk/reward on a multi-week hold....
2025-08-13	CASH
Summary: AZN is in an uptrend with EMA above SMA and price above both, but it's nearing strong resistance at $78.21 after a recent exit, so staying in cash to wait for a dip offering better entry with favorable risk/reward....
2025-08-12	SOLD
Summary: AZN has reached the $75.12 resistance level in a continuing uptrend, prompting an exit from the long position entered at $73.98 to lock in gains near resistance while avoiding potential pullback, with no immediate catalysts and next earnings on November 6, 2025....
2025-08-11	HOLD LONG
Summary: AZN continues in a clear uptrend with EMA above SMA and price above both, holding the long position from $73.98 targeting $78 resistance, supported by oncology advancements and no near-term catalysts, with next earnings on November 6, 2025....
2025-08-08	HOLD LONG
Summary: AZN remains in a clear uptrend with EMA above SMA and price above both, supported by recent Q2 2025 earnings beat and oncology pipeline advancements, justifying continued holding of the long position from $73.98 targeting $78 resistance over the next 1-2 weeks despite minor pullback, with next earnings on November 6, 2025....
2025-08-07	HOLD LONG
Summary: AZN continues in a solid uptrend with EMA above SMA and price above both, bolstered by recent strong H1 2025 earnings, oncology pipeline progress like IMFINZI priority review, and $50B US investment plans, supporting holding the long position from $73.98 targeting $78 resistance over the next 1-2 weeks with no immediate catalysts....
2025-08-06	HOLD LONG
Summary: AZN remains in a clear uptrend with EMA above SMA and price above both, supported by strong H1 2025 earnings, positive oncology pipeline updates including IMFINZI priority review and Gefurulimab Phase III success, and the $50B US investment plan, justifying continued holding of the long position from $73.98 targeting $78 resistance over the next 1-2 weeks amid favorable fundamentals and no immediate catalysts....
2025-08-05	HOLD LONG
Summary: AZN maintains a clear uptrend with EMA above SMA and price above both, bolstered by strong Q2 2025 earnings beat, positive oncology pipeline updates like IMFINZI priority review, and $50B US investment announcement, justifying holding the long position from $73.98 for at least 10-14 days targeting $78 resistance amid ongoing recovery....
2025-08-04	HOLD LONG
Summary: AZN continues in a clear uptrend with EMA above SMA and price above both, supported by strong Q2 2025 earnings, positive guidance, and $50B US investment news, justifying holding the long position from $73.98 targeting $78 resistance amid recent pullback recovery....
2025-08-01	HOLD LONG
Summary: AZN maintains a clear uptrend with EMA above SMA and price above both, supported by strong Q2 2025 earnings beat, unchanged positive guidance, and $50B US investment plans, justifying continued long hold from $73.98 entry targeting $78 resistance despite minor pullback....
2025-07-31	HOLD LONG
Summary: AZN remains in a clear uptrend with EMA above SMA and price above both, despite today's pullback, supported by strong Q2 earnings, positive Gefurulimab trial, and $50B US investment plans, justifying continued long hold targeting $78 resistance. ...
2025-07-29	BUY
Summary: AZN shows a clear uptrend with EMA above SMA and price above both, supported by recent Q2 earnings beat on revenue, positive Phase 3 trial results for Gefurulimab, and reaffirmed 2025 outlook, offering a high-confidence entry post-earnings pullback for a multi-week hold targeting resistance near $78....
2025-07-28	CASH
Summary: AZN's trend is unclear with EMA and SMA tightly bound and recently crossing, while earnings tomorrow on July 29, 2025, introduce high volatility risk without compelling bullish catalysts to justify entry today....
2025-07-25	CASH
Summary: Trend is unclear with tightly bound EMA/SMA and frequent price crossings without volume capitulation, combined with upcoming earnings on July 29 introducing volatility risk, warranting staying in cash to avoid poor entry before the event....
2025-07-24	CASH
Summary: AZN's trend is unclear with EMA slightly below SMA and price above both, while upcoming earnings on July 29, 2025, pose volatility risk without overriding catalysts to justify entry and holding through....
2025-07-23	CASH
Summary: AZN's trend is unclear with EMA below SMA in a tight range, and upcoming earnings on July 29, 2025, introduce volatility risk without overriding catalysts to justify entry before the event....
2025-07-22	SOLD
Summary: Upcoming AZN earnings on July 25, 2025, pose volatility risk without overriding bullish catalysts to justify holding through, especially in unclear trend with EMA below SMA, prompting exit from long at small gain to preserve capital for better post-earnings setup....
2025-07-21	HOLD LONG
Summary: Holding long position as per minimum hold period, with price near support and oversold indicators suggesting potential bounce, despite unclear trend and no immediate catalysts invalidating the trade....
2025-07-18	BUY
Summary: AZN is oversold with RSI at 40, STO K at 22 near lower Bollinger Band, showing potential bounce from recent lows around $68-69, supported by strong fundamentals and positive pipeline developments for a multi-week hold....
2025-07-17	SOLD
Summary: AZN broke below key rising support at ~70 with bearish MACD crossover and weakening momentum, compounded by recent negative trial rumors and sector headwinds, prompting exit from long position after minimal hold to preserve capital....
2025-07-16	BUY
Summary: AZN holds rising support at ~70 with converging MACD signaling potential upside, supported by strong fundamentals and positive oncology pipeline news, offering favorable risk/reward for multi-week hold....